Ednah Akinyi Ojee

Dr. Ednah Akinyi Ojee

University of Nairobi, Nairobi, Nairobi City, Kenya
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CSCaitlin I. Stoddard
Caitlin I. Stoddard
KSKevin Sung
Kevin Sung
EOEdnah Akinyi Ojee
Ednah Akinyi Ojee
JAJudith Adhiambo
Judith Adhiambo
EBEmily R. Begnel
Emily R. Begnel
DLDara Lehman
Dara Lehman
Pre-existing antibodies that bind endemic human coronaviruses (eHCoVs) can cross-react with SARS-CoV-2, which is the betacoronavirus that causes COVID-19, but whether these responses influence SARS-CoV-2 infection is still under investigation and is particularly understudied in infants. In this study, we measured eHCoV and SARS-CoV-1 IgG antibody titers before and after SARS-CoV-2 seroconversion in a cohort of Kenyan women and their infants. Pre-existing eHCoV antibody binding titers were not consistently associated with SARS-CoV-2 seroconversion in infants or mothers; however, we observed a very modest association between pre-existing HCoV-229E antibody levels and a lack of SARS-CoV-2 seroconversion in the infants. After seroconversion to SARS-CoV-2, antibody binding titers to the endemic betacoronaviruses HCoV-OC43 and HCoV-HKU1, and the highly pathogenic betacoronavirus SARS-CoV-1, but not the endemic alphacoronaviruses HCoV-229E and HCoV-NL63, increased in the mothers. However, eHCoV antibody levels did not increase following SARS-CoV-2 seroconversion in the infants, suggesting the increase seen in the mothers was not simply due to cross-reactivity to naively generated SARS-CoV-2 antibodies. In contrast, the levels of antibodies that could bind SARS-CoV-1 increased after SARS-CoV-2 seroconversion in both the mothers and infants, both of whom were unlikely to have had a prior SARS-CoV-1 infection, supporting prior findings that SARS-CoV-2 responses cross-react with SARS-CoV-1. In summary, we found evidence of increased eHCoV antibody levels following SARS-CoV-2 seroconversion in the mothers but not the infants, suggesting eHCoV responses can be boosted by SARS-CoV-2 infection when a prior memory response has been established, and that pre-existing cross-reactive antibodies are not strongly associated with SARS-CoV-2 infection risk in mothers or infants.

11 May 2024 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
EMEleanor J Mitchell
Eleanor J Mitchell
JAJalemba Aluvaala
Jalemba Aluvaala
LBLucy Bradshaw
Lucy Bradshaw
JDJane P Daniels
Jane P Daniels
CECaren Emadau
Caren Emadau
Shalini OjhaShalini Ojha
Shalini Ojha
Preterm birth (< 37 weeks gestation) complications are the leading cause of neonatal mortality. Early-warning scores (EWS) are charts where vital signs (e.g., temperature, heart rate, respiratory rate) are recorded, triggering action. To evaluate whether a neonatal EWS improves clinical outcomes in low-middle income countries, a randomised trial is needed. Determining whether the use of a neonatal EWS is feasible and acceptable in newborn units, is a prerequisite to conducting a trial. We implemented a neonatal EWS in three newborn units in Kenya. Staff were asked to record infants’ vital signs on the EWS during the study, triggering additional interventions as per existing local guidelines. No other aspects of care were altered. Feasibility criteria were pre-specified. We also interviewed health professionals (n = 28) and parents/family members (n = 42) to hear their opinions of the EWS. Data were collected on 465 preterm and/or low birthweight (< 2.5 kg) infants. In addition to qualitative study participants, 45 health professionals in participating hospitals also completed an online survey to share their views on the EWS. 94% of infants had the EWS completed at least once during their newborn unit admission. EWS completion was highest on the day of admission (93%). Completion rates were similar across shifts. 15% of vital signs triggered escalation to a more senior member of staff. Health professionals reported liking the EWS, though recognised the biggest barrier to implementation was poor staffing. Newborn unit infant to staff ratios varied between 10 and 53 staff per 1 infant, depending upon time of shift and staff type. A randomised trial of neonatal EWS in Kenya is possible and acceptable, though adaptations are required to the form before implementation.

27 October 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
CFCarolyn S. Fish
Carolyn S. Fish
POPrestone Owiti
Prestone Owiti
EBEmily R. Begnel
Emily R. Begnel
HIHannah L. Itell
Hannah L. Itell
EOEdnah Akinyi Ojee
Ednah Akinyi Ojee
BCBhavna Chohan
Bhavna Chohan
A multitude of enzyme‐linked immunosorbent assays (ELISAs) has been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies since the coronavirus disease 2019 pandemic started in late 2019. Assessing the reliability of these assays in diverse global populations is critical. This study compares the use of the commercially available Platelia Total Ab Assay (Bio‐Rad) nucleocapsid ELISA to the widely used Mount Sinai spike IgG ELISA in a Kenyan population seroprevalence study. Using longitudinal plasma specimens collected from a mother–infant cohort living in Nairobi, Kenya between May 2019 and December 2020, this study demonstrates that the two assays have a high qualitative agreement (92.7%) and strong correlation of antibody levels ( R 2 = 0.973) in repeated measures. Within this cohort, seroprevalence detected by either ELISA closely resembled previously published seroprevalence estimates for Kenya during the sampling period and no significant difference in the incidence of SARS‐CoV‐2 antibody detection by either assay was observed. Assay comparability was not affected by HIV exposure status. These data support the use of the Platelia SARS‐CoV‐2 Total Ab ELISA as a suitable high‐throughput method for seroprevalence studies in Kenya.

19 December 2024
Verified
Report
Closed access
AEAbiodun Egwuenu
Abiodun Egwuenu
SMSamuel Mwendwa
Samuel Mwendwa
SNSamuel Kariuk Ndegwa
Samuel Kariuk Ndegwa
HEHenry Uguru Ekechi
Henry Uguru Ekechi
EOEdnah Akinyi Ojee
Ednah Akinyi Ojee
PNPatrick Murigu Kamau Njage
Patrick Murigu Kamau Njage